Psychopathological and cognitive effects of therapeutic cannabinoids in multiple clerosis: A double-blind, placebo controlled, crossover study

Clinical Neuropharmacology

Volumn 32, Issue 1, 2009, Pages 41-47

  Aragona, Massimiliano ^a   Onesti, Emanuela ^b   Tomassini, Valentina ^c   Conte, Antonella ^c   Gupta, Shiva ^d   Gilio, Francesca ^c   Pantano, Patrizia ^c   Pozzilli, Carlo ^c   Inghilleri, Maurizio ^c,e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Neurological Centre of Latium   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d WESTCHESTER MEDICAL CENTER   (United States)

^e Dipartimento di Scienze Neurologiche   (Italy)

Author keywords

Anxiety; Cannabinoids; Cognition; Multiple sclerosis; Psychosis

Indexed keywords

AZATHIOPRINE; BACLOFEN; BETA INTERFERON; BOTULINUM TOXIN; CANNABIS; DANTROLENE; DRONABINOL; GLATIRAMER; PLACEBO; SERTRALINE; TIZANIDINE;

ADULT; ARTICLE; BURNING MOUTH SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; EUPHORIA; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; LIMB WEAKNESS; MALE; MENTAL DISEASE; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE SCALE; MULTIPLE SCLEROSIS IMPACT SCALE 29; MYDRIASIS; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SELF RATING ANXIETY SCALE; SIDE EFFECT; SPATIAL ORIENTATION; SYMPTOM CHECKLIST 90; TACHYCARDIA; THINKING IMPAIRMENT; TIME PERCEPTION; TREMOR; VERTIGO; VISUAL ANALOG SCALE; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADULT; CANNABIDIOL; CANNABINOIDS; COGNITION DISORDERS; CROSS-OVER STUDIES; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; STATISTICS AS TOPIC; TETRAHYDROCANNABINOL; TREATMENT OUTCOME;

EID: 67749127624     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181633497     Document Type: Article

References (45)

1. Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend 1996;42:201-207.
2. Stefanis NC, Delespaul P, Henquet C, et al. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004;99:1333-1341.
3. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effect of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004;29: 1558-1572.
4. Henquet C, Krabbendam L, Spauwen J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005;330:11.
5. Degenhardt L, Hall W. Is cannabis use a contributory cause of psychosis? Can J Psychiatry 2006;51:556-565.
6. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: a systematic review. J Psychopharmacol 2005;19:187-194.
7. Dannon PN, Lowengrub K, Amiaz R, et al. Comorbid cannabis use and panic disorder: short term and long term follow-up study. Hum Psychopharmacol 2004;19:97-101.
8. Iversen L. Long-term effects of exposure to cannabis. Curr Opin Pharmacol 2005;5:69-72.
9. Curran HV, Brignell C, Fletcher S, et al. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychoparmacol (Berl) 2002;164:61-70.
10. O'Leary DS, Block RI, Turner BM, et al. Marijuana alters the human cerebellar clock. Neuroreport 2003;14:1145-1151.
11. Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002;287: 1123-1131.
12. Messinis L, Kyprianidou A, Malefaki S, et al. Neuropsychological deficits in long-term frequent cannabis users. Neurology 2006;66: 737-739.
13. Jager G, Kahn RS, Van Den Brink W, et al. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacol (Berl) 2006;185:358-368.
14. Verdejo-Garcia A, Lopez-Torrecillas F, Gimenez CO, et al. Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse. Neuropsychol Rev 2004;14:1-41.
15. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs 2000;60:1303-1314.
16. Killestein J, Uitdehaag BM. Cannabinoids in multiple sclerosis: urgent need for long term trials. J Neurol Neurosurg Psychiatry 2005;76:1612.
17. Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12:639-645.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
19. Derogatis LR. The SCL-90-R: Administration Scoring and Procedures Manual II. Baltimore: Clinical Psychometric Research; 1992.
20. Zung WWK. A rating instrument for anxiety disorders. Psychosomatics 1971;12:371.
21. Fischer JS, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244-250.
22. Parkin D, Rice N, Jacoby A, et al. Use of a visual analogue scale in a daily patient diary: modelling cross-sectional time-series data on health-related quality of life. Soc Sci Med 2004;59:351-360.
23. Herlofson K, Larsen JP. Measuring fatigue in patients with Parkinson's disease - the Fatigue Severity Scale. Eur J Neurol 2002;9:595-600.
24. Hobart J, Lamping D, Fitzpatrick R, et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001;124:962-973.
25. Valiveti S, Stinchcomb AL. Liquid chromatographic-mass spectrometric quantitation of Delta9-tetrahydrocannabinol and two metabolites in pharmacokinetic study plasma samples. J Chromatogr B Analyt Technol Biomed Life Sci 2004;803:243-248.
26. Rosti E, Hamalainen P, Koivisto K, et al. The PASAT performance among patients with multiple sclerosis: analyses of responding patterns using different scoring methods. Mult Scler 2006;12:586-593.
27. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10:417-424.
28. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-819.
29. Green B, Young R, Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 2005;187:306-313.
30. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;31:253.
31. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10:417-424.
32. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-819.
33. Collin C, Davies P, Mutiboko IK, et al. Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14: 290-296.
34. Chong MS, Wolff K, Wise K, et al. Cannabis use in patients with multiple sclerosis. Mult Scler 2006;12:646-651.
35. Monshouwer K, Van Dorsselaer S, Verdurmen J, et al. Cannabis use and mental health in secondary school children. Findings from a Dutch survey. Br J Psychiatry 2006;188:148-153.
36. Arendt M, Rosenberg R, Fjordback L, et al. Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects. Psychol Med 2007;37:935-945.
37. Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002;58:1404-1407.
38. Ventegodt S, Merrick J. Psychoactive drugs and quality of life. Sci World J 2003;18:694-706.
39. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005;76:1664-1669.
40. Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997;3:44-48.
41. Khong E, Sim MG, Hulse G. Benzodiazepine dependence. Aust Fam Phys 2004;33:923-926.
42. Simon GE, Ludman EJ. Outcome of new benzodiazepine prescriptions to older adults in primary care. Gen Hosp Psychiatry 2006;28:374-378.
43. Brinker A, Bonnel RA, Beitz J. Abuse, dependence, or withdrawal associated with tramadol. Am J Psychiatry 2002;159:881.
44. Aragona M. Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report. Clin Neuropharmacol 2000;23: 281-283.
45. Guy GW, Robson PJ. A phase 1, open-label, four way crossover study to compare the pharmacokinetic profiles of a single dose of 29mg of a cannabis-based medicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers. J Cannabis Ther 2003;3/4:121-152.